Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael J. Klepper
Observed names:
M Klepper,
M. Klepper,
Michael J Klepper,
Michael Jacob Klepper,
Michael Klepper
Institutions:
Regional Municipality of Durham,
Compass Oncology,
Cancer Center of Kansas,
Oncology Institute of Hope and Innovation,
Durham Public Schools,
Heron Therapeutics (United States),
The US Oncology Network
show all 7
Observed institutions:
Regional Municipality of Durham,
Compass Oncology,
Cancer Center of Kansas,
Oncology Institute of Hope and Innovation,
Durham Public Schools,
Heron Therapeutics (United States),
The US Oncology Network,
Boston Pharmaceuticals (United States)
show all 8
ORCID:
0000-0002-6951-6676
Observed ORCID:
0000-0002-6951-6676
OpenAlex ID:
A5021312005
The Periodic Safety Update Report as a Pharmacovigilance Tool
2004
·
Michael J Klepper
·
Drug Safety
·
51
Subclinical Hypothyroidism and Euthyroid Sick Syndrome in Patients With Moderate-to-severe Congestive Heart Failure
1996
·
Neil R. Manowitz
, Gilbert H. Mayor
, et al.
·
American Journal of Therapeutics
·
29
APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy
2016
·
Ian D Schnadig
, Richy Agajanian
, et al.
·
Future Oncology
·
25
PDF
Drug Safety Data: How to Analyze, Summarize, and Interpret to Determine Risk
2010
·
Michael J. Klepper
, Barton Cobert
·
14
Individual Case Safety Reports – How to Determine the Onset Date of an Adverse Reaction: A Survey
2011
·
Michael J. Klepper
, Brian Edwards
·
Drug Safety
·
12
Carteolol Treatment of Essential Hypertension: A Long-Term Study of Safety and Efficacy
1986
·
Robert R Luther
, Clemeth J Maurath
, et al.
·
Journal of International Medical Research
·
7
Long-Term Treatment of Angina Pectoris with Carteolol: A New Beta-Adrenergic Receptor Blocking Agent
1986
·
Robert R Luther
, Harriet N Glassman
, et al.
·
Journal of International Medical Research
·
7
Survey of Safety Information in the Investigator’s Brochure: Inconsistencies and Recommendations
2018
·
Michael Jacob Klepper
, Leander Fontaine
·
Therapeutic Innovation & Regulatory Science
·
4
APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis
2017
·
Lee Schwartzberg
, Michael Mosier
, et al.
·
The Journal of Community and Supportive Oncology
·
4
Phase 3 trial of APF530 vs. ondansetron, each with a neurokinin 1 antagonist and corticosteroid, for prevention of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy regimens (MAGIC Trial): Outcomes in cisplatin-based regimen
2016
·
L. Schwartzberg
, M. Mosier
, et al.
·
Gynecologic Oncology
·
2
Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial
2016
·
I Schnadig
, R Agajanian
, et al.
·
Cancer Research
·
2
Letters
1994
·
Susan E. Malecha
, PharmD
, et al.
·
Spine
·
2
Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.
2015
·
Ian D. Schnadig
, Richy Agajanian
, et al.
·
Journal of Clinical Oncology
The “Dynamic” Integrated Database for Pre-Marketing Risk Assessment – A Paradigm Shift
2012
·
Michael J. Klepper
·
Frontiers in Pharmacology
PDF
くすりの安全性を科学する : リスクを見極めるために,データをどう分析し,まとめ,解釈するか
2012
·
Michael J. Klepper
, Barton Cobert
, et al.
Getting your message out: a new prescription.
1985
·
M Klepper
·
PubMed
Show more works
View as search
Works count:
19
Citation count:
159
H-index:
7
I10-index:
5
Year
Topic
Type